```html

Portal Hypertension

What is Portal Hypertension?

Portal hypertension (PH) is an elevation of blood pressure within the portal venous system, the network of veins that carries blood from the gastrointestinal (GI) tract, spleen, and pancreas to the liver. Normal portal pressure is 5‑10 mm Hg; a pressure gradient (the hepatic venous pressure gradient, HVPG) > 10 mm Hg is considered abnormal, and > 12 mm Hg is associated with the development of complications such as variceal bleeding.

The condition is usually a consequence of increased resistance to blood flow through the liver (intra‑hepatic) or obstruction of flow outside the liver (pre‑ or post‑hepatic). Because the portal system has limited capacity to handle high pressure, the body forms collateral pathways (varices) that can rupture and bleed.

Sources: Mayo Clinic; American College of Gastroenterology (ACG) guideline 2022.

Common Causes

The underlying disease can be grouped into three categories: pre‑hepatic, intra‑hepatic, and post‑hepatic. The most frequent causes are:

• Cirrhosis – most common worldwide; usually due to chronic hepatitis B or C, alcohol, non‑alcoholic fatty liver disease (NAFLD), or autoimmune hepatitis.
• Schistosomiasis – parasitic infection prevalent in parts of Africa, the Middle East, and South America; causes peri‑portal fibrosis.
• Non‑cirrhotic portal fibrosis (NCPF) / idiopathic portal hypertension – fibrosis limited to portal tracts without nodular regeneration.
• Budd‑Chiari syndrome – obstruction of hepatic veins leading to post‑hepatic hypertension.
• Congenital hepatic fibrosis – a genetic disorder often seen in children.
• Portal vein thrombosis – clot formation within the portal vein, secondary to hypercoagulable states, abdominal infections, or trauma.
• Congestive heart failure (right‑sided) – elevates central venous pressure, which backs up into the hepatic veins.
• Veno‑occlusive disease (VOD) / sinusoidal obstruction syndrome – often a complication of chemotherapy or bone‑marrow transplant.
• Severe hepatic steatosis (fatty liver) progressing to fibrosis – increasingly common with obesity and type 2 diabetes.
• Rare infiltrative diseases – such as sarcoidosis, amyloidosis, or hemochromatosis that thicken the liver sinusoids.

Associated Symptoms

Many patients are asymptomatic early on. When symptoms appear, they usually reflect the body’s attempt to bypass the high‑pressure portal system:

• Ascites – accumulation of fluid in the abdominal cavity causing swelling and discomfort.
• Splenomegaly – enlarged spleen, often leading to low platelet counts (thrombocytopenia) and anemia.
• Gastro‑esophageal varices – dilated veins in the esophagus or stomach; may cause “coffee‑ground” vomiting if they bleed.
• Encephalopathy – confusion, personality changes, or asterixis due to toxin buildup when liver function declines.
• Caput medusae – visibly dilated abdominal veins radiating from the umbilicus.
• Hematemesis or melena – vomiting blood or black tarry stools, indicating variceal hemorrhage.
• Abdominal discomfort – fullness, early satiety, or a feeling of pressure from ascites.
• Jaundice – yellowing of skin and eyes when underlying liver disease progresses.

Sources: Cleveland Clinic; NIH Liver Disease Portal.

When to See a Doctor

Prompt medical evaluation is essential if you notice any of the following:

• New or worsening abdominal swelling (ascites).
• Persistent nausea, loss of appetite, or early satiety.
• Vomiting blood, or passing black/tarry stools.
• Sudden, severe abdominal pain (possible portal vein thrombosis).
• Persistent fatigue, confusion, or personality changes.
• Unexplained bruising or bleeding (low platelets from splenic sequestration).

Even in the absence of acute bleeding, routine follow‑up with a hepatologist or gastroenterologist is recommended for people with known liver disease.

Diagnosis

Evaluation combines clinical assessment, blood work, imaging, and sometimes invasive measurements.

Clinical Examination

• Physical signs: splenomegaly, caput medusae, ascites, jaundice.
• Evaluation of stigmata of chronic liver disease (spider angiomata, palmar erythema).

Laboratory Tests

• Complete blood count – may reveal anemia, leukopenia, thrombocytopenia.
• Liver function panel – ALT, AST, bilirubin, alkaline phosphatase, albumin.
• Coagulation profile (INR, PT) – assesses synthetic function.
• Serologies for hepatitis B, C, HIV, and autoimmune markers.
• Serum‑Ascites Albumin Gradient (SAAG) if ascites is present – helps determine portal vs. non‑portal causes.

Imaging Studies

• Ultrasound with Doppler – first‑line; evaluates portal vein diameter, flow direction, and detects thrombosis.
• CT or MRI – provides detailed anatomy, identifies masses, varices, and collateral vessels.
• Transient elastography (FibroScan) – non‑invasive measurement of liver stiffness, correlates with risk of PH.

Invasive Assessment

• Hepatic Venous Pressure Gradient (HVPG) – measured via a catheter inserted into a hepatic vein; the gold standard for quantifying portal pressure.
• Upper endoscopy (EGD) – screens for esophageal or gastric varices; recommended for all patients with cirrhosis.

Treatment Options

Treatment aims to lower portal pressure, manage complications, and treat the underlying cause.

Medical Management

• Non‑selective beta‑blockers (NSBBs) – propranolol or carvedilol reduce cardiac output and splanchnic blood flow; first‑line for primary prophylaxis of variceal bleeding.
• Vasopressin analogs (e.g., terlipressin) – used in acute variceal hemorrhage to constrict splanchnic vessels.
• Diuretics – spironolactone ± furosemide for ascites control; monitor electrolytes and renal function.
• Antibiotic prophylaxis – fluoroquinolones or ceftriaxone in cirrhotic patients with GI bleeding to prevent infections.
• Octreotide or somatostatin analogs – reduce portal inflow during active bleeding.
• Lactulose & rifaximin – treat hepatic encephalopathy.

Endoscopic & Radiologic Interventions

• Endoscopic band ligation (EBL) – first‑line for existing esophageal varices.
• Transjugular intrahepatic portosystemic shunt (TIPS) – creates a channel between portal and hepatic veins, lowering pressure; reserved for refractory variceal bleeding or refractory ascites.
• Balloon‑occluded retrograde transvenous obliteration (BRTO) – used for gastric varices in select centers.

Surgical Options

• Portosystemic shunt surgery (e.g., distal splenorenal shunt) – rarely performed today due to TIPS availability.
• Liver transplantation – definitive cure for portal hypertension secondary to end‑stage cirrhosis.

Home & Lifestyle Measures

• Low‑sodium diet (≤ 2 g/day) to control ascites.
• Fluid restriction only if hyponatremic (< 125 mmol/L).
• Weight management and regular exercise to improve NAFLD‑related liver disease.
• Avoid alcohol completely; even modest intake worsens portal pressure.
• Vaccinations – hepatitis A & B, pneumococcal, influenza, and COVID‑19.
• Regular monitoring of blood counts and renal function when on diuretics or NSBBs.

Prevention Tips

While portal hypertension itself cannot always be prevented, many of its root causes are modifiable:

• Vaccinate against hepatitis B and maintain safe practices to prevent hepatitis A and C.
• Limit alcohol – adhere to ≤ 14 drinks per week for men and ≤ 7 for women, or abstain if liver disease is present.
• Maintain a healthy weight – target BMI 18.5‑24.9; adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• Control diabetes and hyperlipidemia – good glycemic and lipid control slows NAFLD progression.
• Stay physically active (≥ 150 minutes of moderate exercise weekly).
• Use medications responsibly; avoid unnecessary hepatotoxic drugs (e.g., high‑dose acetaminophen, certain herbal supplements).
• Screen high‑risk individuals (chronic hepatitis, family history of liver disease) with ultrasound and FibroScan every 1‑2 years.

Emergency Warning Signs

Portal hypertension is a serious but manageable condition when identified early and treated appropriately. If you have risk factors such as chronic liver disease, a history of hepatitis, or unexplained abdominal swelling, schedule an appointment with your primary care provider or a hepatologist for evaluation.

References:

1. Mayo Clinic. “Portal Hypertension.” Updated 2023. https://www.mayoclinic.org
2. American College of Gastroenterology. “Guidelines for the Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis.” 2022.
3. Cleveland Clinic. “Portal Hypertension Overview.” https://my.clevelandclinic.org
4. National Institutes of Health – Liver Disease Portal. “Causes and Complications of Portal Hypertension.” 2021.
5. World Health Organization. “Hepatitis B and C Fact Sheets.” 2024.
6. European Association for the Study of the Liver (EASL). “Management of Variceal Hemorrhage.” 2022.

```